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ABSTRACT  24 
Context & Objectives The Controlled Antenatal Thyroid Screening (CATS) study was 25 
the first randomised controlled trial to investigate effects of treating suboptimal-26 
gestational-thyroid-function (SGTF) on child cognition.  Since observational studies 27 
indicated that SGTF may also increase symptoms of autism and attention deficit 28 
hyperactivity disorder (ADHD), the CATS cohort was used to investigate whether 29 
treatment of mothers affected their children’s behavior.     30 
Design & Participants Mothers (N=475) completed 3 questionnaires, strengths and 31 
difficulties (SDQ), attention deficit hyperactivity disorder (ADHD) and social 32 
communication (SCQ, used as a screen for autism spectrum disorder (ASD)), about 33 
their children (aged 9.5 years). Group comparisons of total scores, numbers of children 34 
above clinical thresholds and association between high maternal FT4 (>97.5th 35 
percentile of the UK cohort, ‘over-treated’) and child neurodevelopment were reported.  36 
Results There were no differences in total scores between normal-GTF (n=246), 37 
treated (n=125) and untreated (n=104) SGTF groups. More children of treated mothers 38 
scored above clinical thresholds, particularly the over-treated. Scores were above 39 
thresholds in SDQ conduct 22% vs 7%, SCQ total scores 7% vs 1%, and ADHD 40 
hyperactivity 17% vs 5% when comparing over-treated (n=40) and untreated (N=100) 41 
respectively. We identified significantly higher mean scores for SDQ conduct (adjusted 42 
mean difference (AMD) 0.74, 95% confidence interval (CI) 0.021 to 1.431, P=0.040, 43 
effect size 0.018) and ADHD hyperactivity (AMD 1.60, CI 0.361 to 2.633, P=0.003, 44 
effect size 0.028) comparing over-treated with normal-GTF children. 45 
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Conclusions There was no overall association between SGTF and offspring ADHD, 46 
ASD or behavior questionnaire scores. However, children of ‘over-treated’ mothers 47 
displayed significantly more ADHD symptoms and behavioral difficulties than normal-48 
GTF. Thyroxine supplementation during pregnancy requires monitoring to avoid over-49 
treatment. 50 
PRÉCIS 51 
We investigated effects of treating sub-optimal gestational thyroid function (SGTF) 52 
on child behaviour. No associations found between SGTF & offspring behaviour; 53 






INTRODUCTION  58 
The cognitive impairment displayed in children with congenital hypothyroidism or born 59 
to mothers with iodine deficiency illustrates the essential role of thyroid hormones, 60 
triiodothyronine (T3) and thyroxine (T4), in brain development (1). Although fetal T3 61 
receptors in the human brain can be detected from about 10 weeks gestation and 62 
increase 50 fold by 16 weeks, the thyroid develops relatively late with full function 63 
being acquired at around 36 weeks gestation (1); thus thyroid hormones must be 64 
supplied via placental transfer (2). Sub-optimal gestational thyroid function (SGTF) 65 
(classified as low T4 and/or high thyroid stimulating hormone (TSH) values, or both) 66 
in pregnancy can occur in women with no previous thyroid dysfunction. Children born 67 
to mothers with SGTF have been reported to have lower IQ compared with children 68 
born to euthyroid mothers (3-11). However, two large randomized controlled trials 69 
(RCTs) found no evidence of thyroid hormone treatment improving the IQ of children 70 
born to mothers with SGTF (12,13) tested at ages 3 and 5 respectively. These results 71 
were confirmed recently in a follow-up to the first study, in children aged 9 (14).  72 
In addition to intelligence, SGTF may also affect other aspects of child 73 
neurodevelopment; specifically attention deficit hyperactivity disorder (ADHD, 74 
characterised by hyperactivity, inattention and impulsiveness) and autism spectrum 75 
disorder (ASD, characterised by social and communication problems, and repetitive 76 
behaviors). Multiple observational studies have reported higher ADHD scores in 77 
children born to mothers with SGTF, particularly hypothyroxinaemia, compared to 78 
controls (3,15-19). Childhood ASD has been reported to be increased in those born to 79 
mothers with SGTF (20,21). Maternal thyroid peroxidase autoantibodies, markers of 80 
thyroid autoimmunity, are also associated with increased ADHD (22) and ASD risk 81 
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(23) in offspring. In contrast, others report no link between SGTF and ADHD or ASD 82 
symptoms in the child (20,24,25). 83 
The two RCTs described above (12,13) included additional psychological 84 
assessments of behavioral and social competency plus attention. Neither reported any 85 
differences in these parameters in children of treated and untreated mothers; although 86 
they were not powered specifically for these aspects. Furthermore, data from children 87 
of mothers with normal-GTF were not collected. The current study is an extension of 88 
the first RCT of treatment of SGTF during pregnancy (12) in which the offspring were 89 
examined for behavior, social competency and attention after long-term follow-up. The 90 
inclusion of children of normal-GTF mothers enabled us to assess whether there is a 91 
deficit in neurodevelopment requiring treatment.  92 
Furthermore, since a number of mothers demonstrated high FT4 concentrations 93 
suggesting a degree of over-treatment, we were also interested in the effects of high-94 
FT4 on child neurodevelopment outcomes. The rationale for this derives from studies 95 
by Korevaar and colleagues, who reported adverse effects on brain morphology and 96 
cognition of both too little and too much thyroid hormone (26). In addition, a recent 97 
study from Maraka et al, demonstrated worse obstetric outcomes such as pre-term 98 
delivery and pre-eclampsia in treated women with SGTF (27). 99 
MATERIALS AND METHODS 100 
The Controlled Antenatal Thyroid Screening study 101 
We report a follow-up to a treatment trial, the Controlled Antenatal Thyroid Screening 102 
Study (CATS) (12), in which women were screened at a median of 12 weeks 3 days’ 103 
gestation between June 13, 2002 and May 31, 2006.  Briefly, in CATS-I (12) midwives 104 
and obstetric care-givers in the UK and Italy recruited ~22,000 women (excluding 105 
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history of thyroid disease, twin pregnancies, maternal age <18 years or gestational 106 
age >15 weeks and 6 days), at their first antenatal hospital appointment. Participants 107 
were randomized, by computer generated block design, either to screen or control 108 
groups; both provided serum samples at recruitment with the screen group having 109 
their thyroid function tested immediately and the controls after their child was born 110 
(sera stored at -40◦C).  If the mother’s FT4 was <2.5th percentile and/or TSH >97.5th 111 
percentile, they were classified as having SGTF; percentiles being calculated from the 112 
CATS cohort. Women in the screen group with SGTF were treated with levothyroxine 113 
(starting dosage 150µg) for the remainder of their pregnancies. Dosages were 114 
adjusted where necessary, to maintain a serum TSH of 0.1-1.0mlU/L, following 115 
measurement of TSH and FT4 6 weeks after treatment was initiated and at 30 weeks 116 
gestation. SGTF women diagnosed after delivery were advised to visit their general 117 
practitioner for further management. The primary outcome was children’s IQ at age 3 118 
from 390 (303 in the UK) treated (screen) and 404 (306 in the UK) untreated (control) 119 
mothers (assessors blinded to treatment group). A further 20,789 (15,593 in the UK) 120 
women made up the normal-GTF group and recruitment ended when sufficient 121 
numbers, determined by prior power calculation, had been reached. Figure 1 shows 122 
the study flow chart of the UK participants. 123 
 124 
Follow-up of children at ages 7-10 years; current data  125 
Inclusion criteria were mothers living in the UK and from the CATS-I cohort whose 126 
children were aged 7 to 10 years. Offspring follow-up data were collected between 127 
August 8, 2011 and August 7, 2015.  The target sample size of 480 participants was 128 
pre-determined and informed by prior power calculations to assess cognition. Samples 129 
of 120 from each of the treated and untreated SGTF groups provided 80% power with 130 
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a 5% two-sided significance level to detect a 1.97 increase in odds of IQ <85 in 131 
untreated SGTF offspring assuming treated SGTF offspring have a mean IQ of 100 132 
with a SD of 15. An additional 240 participants from the normal GTF group, randomly 133 
selected from the 15,593 UK cohort, were used to assess interaction with maternal 134 
thyroid status and levothyroxine treatment on offspring IQ. 135 
For full details see Hales et al 2014 (28). 136 
CATS mothers from the UK SGTF treated and untreated groups (n=609) were invited 137 
to participate by letter. The Welsh Demographics Service and Patient Data Registrar 138 
provided current addresses. Those without SGTF in the control and screen branches 139 
of the RCT, were pooled (UK n=15,593), and named ‘normal-GTF’; a random sample 140 
of 4,000 from this group was also invited to participate. Data were collected at a 141 
research centre, via a home visit, or by post; this approach was used to maximise the 142 
follow-up rate. Informed consent was provided by all mothers who completed the 143 
questionnaires. 144 
Results of cognitive assessments in the children have been reported (14). 145 
Cardiovascular, metabolic, bone data and DNA samples were also collected in those 146 
participants attending the visit at the research centre but are not described here (ms 147 
in preparation).  148 
Mothers  (mean age 31 (SD 5.12) years) were asked to complete three questionnaire 149 
measures on their children (mean age 9.5 (SD 0.77) years): The Strengths and 150 
Difficulties Questionnaire (SDQ) (29), The Child ADHD Questionnaire (ADHDq) (30), 151 
and the Social Communication Questionnaire (SCQ) (31). The SDQ consisted of 25 152 
items, scored by a Likert scale (0-2), grouped into five subscales; Hyperactivity (5 153 
ADHD items), Emotional symptoms, Conduct problems, Peer problems, and Pro-154 
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social behavior as well as a total score. The SDQ provides a measure of child mental 155 
health difficulties, has been internationally validated and has good psychometric 156 
properties (32-35). The ADHDq consists of 18 items addressing ICD-10 symptoms by 157 
a Likert scale (0-3, Thapar et al.(30)); subscales include inattention, hyperactivity, and 158 
impulsivity. The Social Communication Questionnaire has good external validity (36) 159 
and is one of the most widely adopted screening tools for ASD (37). The SCQ 160 
generates a total score from ‘yes’/‘no’ answers; a score of  ≥15, indicates possible 161 
ASD (38). Data were collected, inputted, and cleaned by one researcher who was 162 
blinded to participant study group. 163 
Statistical analysis 164 
All analyses (unless otherwise stated) were adjusted for child gender, maternal age at 165 
time of consent into CATS, whether the mother breastfed for over one month, and 166 
quintile of social deprivation (the lower the quintile the more deprived, quintiles 167 
enabled comparisons between Welsh and English postcodes); these variables have 168 
been reported previously to be associated with questionnaire scores (39-47). Child 169 
age was not included as a covariate given the narrow age range of the children (3 170 
years).  171 
Descriptive statistics were calculated to identify any potential recruitment bias in the 172 
three groups; continuous variables are presented as means (standard deviations) and 173 
categorical data as percentages (unless otherwise stated). Thyroid function test 174 
results at time of consent into CATS are presented per group, as well as the treated 175 
SGTF group’s additional test results. As a proportion of CATS mothers had high FT4 176 
concentrations (26), the study was able to analyse an ‘over-treatment’ effect; a FT4 177 
measurement >17.7pmol/L at either 20 weeks or 30 weeks’ gestation as defined by 178 
the top 2.5th percentile of FT4 in the entire CATS UK cohort at consent into the RCT. 179 
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The over-treatment value was calculated using a large sample-size (n=16,346) and 180 
was higher than the upper limit of the regional reference range. Mean FT4 and median 181 
TSH values of those who were over-treated were compared to the optimally treated 182 
mothers (FT4 <17.6pmol/L). Effects of the treated SGTF group’s thyroid function tests 183 
throughout pregnancy were related to the questionnaire subdomains and total scores.  184 
List-wise deletion was applied for questionnaires having >15% missing data 185 
(previously reported 10-20% acceptable (48,49), with >15% requiring consideration 186 
(50)), leading to exclusion of 21 participants. Of the remaining 454 participants 187 
(normal-GTF=237, treated SGTF=117, untreated SGTF=100), 54 (11.9%) had 188 
missing data; total values of missing data were n=85 (0.2%). The remaining 189 
participants’ data were analysed by Little’s missing completely at random test (non-190 
significant), with missing values replaced by the ‘series mean’ in SPSS (51). 191 
All Kolmogorov-Smirnov (and Shapiro-Wilk) normality tests were returned as p <0.001 192 
for all questionnaires on every totalled domain. However, means and medians 193 
appeared close and skewness and kurtosis ranges were largely just above ± 1 and 194 
thus were returned as normal with caution.  195 
In the primary analysis, we compared the mean total scores from the three 196 
questionnaires administered to the normal-GTF, treated and untreated SGTF groups. 197 
This was by a multivariate analysis of covariance (MANCOVA), which was followed by 198 
univariate tests and pairwise comparisons that were Bonferroni corrected, where 199 
relevant.  200 
In the secondary analysis, the frequency of children scoring above the questionnaire 201 
thresholds that indicate likely disorder was presented to enable comparisons between 202 
the groups. For SDQ, the clinically significant cut-offs were adopted, those classified 203 
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as ‘high’ were in the 90-95th percentile range, and ‘very high’ were above the 95th 204 
percentile (29). For the ADHDq, the authors calculated the SDs (30); scores >2SDs 205 
were reported. For the SCQ, scores >15 were identified as the child potentially having 206 
an ASD (31); a UK sample found a prevalence of 4-5% for scores >15 (52).  207 
The exploratory analysis investigated the effect of treatment. Mean scores from the 208 
questionnaires (total and subdomains) were compared between the normal-GTF, 209 
untreated SGTF, optimally treated SGTF (FT4 <17.6pmol/L), and over-treated SGTF 210 
(FT4 >17.7pmol/L). Further exploratory analyses are in the Supplemental Material, 211 
including effects of hypothyroxinemia or subclinical hypothyroidism and varying levels 212 
of FT4 following treatment.  213 
Standard regression analysis was performed to compare behavior of participating 214 
children at age 3 (Child behavior check-list) and age 9 (strengths and difficulties 215 
questionnaire). 216 
All statistical analyses were performed with SPSS version 20 software. P<0.05 was 217 
considered significant. 218 
RESULTS 219 
Characteristics of the cohort 220 
A total of 485 women/child pairs participated but 10 were excluded (9 ineligible, one 221 
whose results were deemed unreliable due to their approach to the assessment) 222 
leaving 475 who completed the questionnaires (normal-GTF=246, treated SGTF=125, 223 
and untreated SGTF=104); table 1 reports their demographic data. The SGTF groups 224 
had younger children participating (by four months) than the normal-GTF group, and 225 
the treated SGTF also had significantly younger mothers by ten months. The treated 226 
SGTF had a higher median baseline TSH compared to the untreated SGTF group; this 227 
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suggested a potential recruitment bias and was reflected in SGTF group age 3 to age 228 
9 comparisons; supplemental data table 1 (53).  229 
Pregnancy thyroid function tests of the treated SGTF group at 20 weeks’ gestation 230 
identified a mean (SD) FT4 of 16.2pmol/L (2.89), reducing to 15.5pmol/L (2.47) at 30 231 
weeks; median TSH values at 20 and 30 weeks gestation were 0.3mIU/L at both time 232 
points. Of these women, 41 were over-treated, with FT4 concentration >17.7pmol/L at 233 
20 or 30 weeks’ gestation (see supplemental material for figures); with 13 of these 234 
sustaining over-treatment throughout their pregnancies. The mean FT4 235 
concentrations at 20 weeks and 30 weeks for the over-treated group were 19.2pmol/L 236 
(2.53) and 17.8pmol/L (2.46), respectively, whilst median TSH values at these times 237 
were below target at 0.08mIU/L and 0.05mIU/L, respectively. In the remaining 238 
optimally treated SGTF group, the mean FT4 concentrations at 20 weeks’ and 30 239 
weeks’ gestation were 14.8pmol/L (1.78) and 14.5pmol/L (1.73), respectively, with 240 
median TSH values of 0.52mIU/L and 0.35mIU/L.  241 
Main analyses 242 
After removing participants with >15% missing data, 454 were analysed, revealing no 243 
significant differences between the means of the 3 administered questionnaires  (table 244 
2) in the normal-GTF, treated SGTF and untreated SGTF groups (P=0.261). Total 245 
questionnaire scores comparing the three participant groups were significantly 246 
affected by child gender (/sex), mother age at time of consent and social deprivation 247 
(P=0.001, P=0.030, and P=0.001, respectively). Higher questionnaire scores were 248 
more likely for male children and children born to younger mothers during pregnancy 249 
or to families with greater social deprivation.  250 
Secondary and Exploratory Analyses 251 
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At the point of recruitment into CATS-I, there was a negative association between 252 
maternal FT4 level and aspects of child behaviour assessed at age 9; i.e. children of 253 
mothers with low FT4 before any treatment tended to have higher questionnaire 254 
scores indicating more behaviour problems. However, the association between child 255 
behaviour problems and FT4 in treated mothers was positive at 20 weeks’ gestation 256 
(figure 2). Thus we investigated the possible effects of over-treatment as defined by 257 
the top 2.5th percentile of FT4 in the CATS UK cohort at recruitment (N=16,346, 258 
FT4>17.7 pmol/L). We observed significantly higher mean scores for some domains: 259 
SDQ conduct (adjusted mean difference (AMD) 0.74, 95% confidence interval (CI) 260 
0.021 to 1.431, P=0.040, effect size 0.018) and ADHD hyperactivity (AMD 1.60, CI 261 
0.361 to 2.633, P=0.003, effect size 0.028) in over-treated compared with normal-GTF. 262 
Furthermore, individuals within each group had ‘high scores’ on domains reported in 263 
the analyses (table 3); these were defined as clinically significant cut-offs (SDQ), 264 
standard deviations calculated by Thapar et al.(30) (ADHDq), and a score >15 265 
indicative of a child potentially having an ASD (31) (SCQ). The largest and significant 266 
percentage differences were noted on SDQ Conduct, SDQ Hyperactivity, ADHDq 267 
Hyperactivity, and SCQ Total; the treated SGTF had proportionately more than twice 268 
as many individuals in the highest classifications compared to the normal-GTF and 269 
untreated SGTF, which appeared to be driven by those children born to over-treated 270 
mothers. When comparing the normal-GTF and untreated SGTF children, we did not 271 
observe any difference between numbers of individuals in the highest classifications.  272 
Effect of subclinical hypothyroidism, hypothyroxinemia and overt hypothyroidism 273 
Similar non-significant differences were found between the normal GTF (n=237), 274 
treated (n=67), and untreated (n=49) subclinical hypothyroid groups for total 275 
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questionnaire scores (P=0.909). When exploring the effect of treatment to the 276 
17.7pmol/L threshold, there was also no difference in mean scores; supplemental data 277 
table 2  278 
Total questionnaire scores were not significantly different between the normal GTF 279 
(n=237), treated (n=36) and untreated (n=44) hypothyroxinaemia groups; 280 
supplemental data table 3.  281 
There were 8.55% (n=10) of the treated SGTF group, and 9.00% (n=9) of the untreated 282 
SGTF group classified as having overt hypothyroidism (OH). Comparing these groups 283 
(combined) with the normal GTF for total questionnaire scores identified a significant 284 
difference at the multivariate level (V=0.063, F(6,496)=2.669, P=0.015, ηp2=0.031), 285 
with a difference found for ADHD Total scores (F(2,249)=4.680, P=0.010, ηp2=0.036). 286 
The untreated OH group had significantly higher scores compared to the normal GTF 287 
for ADHD Total (P=0.022 (0.945, 16.876)). 288 
When exploring the effect of treatment to the 17.7pmol/L threshold for maternal FT4, 289 
there was a difference at the multivariate level (V=0.203, F(27,726)=1.948, P=0.003 290 
ηp2=0.068). At the univariate level SDQ Conduct (F(3,248)=4.402, P=0.005, ηp2=0.051), 291 
ADHD Hyperactivity (F(3,248)=5.665, P=0.001, ηp2=0.064), and ADHD Total 292 
(F(3,248)=3.487, P=0.016, ηp2=0.040) were significantly different. The over-treated OH 293 
group had significantly higher scores for SDQ Conduct (P=0.038 (0.072, 4.273) and 294 
ADHD Hyperactivity (P=0.020 (0.357, 6.597) compared to the normal GTF. Again, for 295 
ADHD Total, the untreated OH had significantly higher scores than the normal GTF 296 
(P=0.045 (0.117, 7.693).  297 
Children born to mothers who were untreated for OH in pregnancy, had higher scores 298 
for the Child ADHD Questionnaire, optimal treatment improved this with some means 299 
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moving closer to those of the normal GTF; supplemental data table 4. Over-treatment 300 
for OH had a significant effect on the same domains identified with the entire SGTF 301 
sample; SDQ Conduct and ADHD Hyperactivity. Caution is advised, however, as the 302 
sample sizes are small for OH. 303 
Finally, we applied standardised regression analysis to compare behavior assessed 304 
at age 3, using the CBCL, and at age 9, using the SDQ.  We observed that behavior 305 
at ages 3 and 9 was highly correlated B (Std) = 0.54 (95%CI 0.48 – 0.66) p< 0.001, 306 
with variation at age 3 predicting 30% of the variation at age 9. Adjusting for other key 307 
factors such as sex, social class, maternal age and breastfeeding had no substantial 308 
impact on relationship or effect estimates. 309 
DISCUSSION 310 
We have applied well-validated questionnaires to assess neurodevelopment and 311 
behavior in a large cohort of children born to mothers recruited to CATS-I, the first 312 
RCT to explore the effect of levothyroxine treatment on childhood outcomes. In 313 
addition, our inclusion of children from normal-GTF mothers allowed us to investigate 314 
whether SGTF has any effect on conduct and hyperactivity.   315 
We found no difference in the mean total scores of questionnaires to assess ADHD 316 
and ASD in children of mothers with normal-GTF compared with SGTF, whether 317 
treated or not. Results were the same when considering treated and untreated 318 
hypothyroxinemia and subclinical hypothyroidism separately, although numbers were 319 
inevitably smaller in the sub-sets. Boys, children born to younger mothers or to socially 320 
deprived families were more likely to have higher scores. FT4 was negatively 321 
associated with measures of hyperactivity in children of treated mothers at recruitment 322 
but positively associated after thyroxine supplementation. Reflecting this switch, there 323 
were significantly more children of treated mothers with scores above clinical 324 
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thresholds for conduct and hyperactivity than normal-GTF mothers. In particular, there 325 
were either significantly more children of over-treated mothers above defined cut-offs 326 
for these parameters or with mean scores significantly higher than the untreated SGTF 327 
or normal-GTF groups respectively. 328 
 329 
We are aware that our study sample may be biased but group means were within 330 
±1SD of the ADHDq mean (24) or similar to the means reported for the SDQ and SCQ 331 
from other large UK cohorts (52) suggesting that participants are representative. 332 
However, numbers in the SGTF groups, especially untreated, were below our target 333 
and recruitment was a challenge from the outset, mainly because participants had re-334 
located and did not respond to invitation.   335 
 336 
Incomplete questionnaires were minimised by spot-checks and thus less than 1% of 337 
participants were excluded. However, questionnaires were completed only by the 338 
mothers and the study would have benefited from the child’s mental health and 339 
neurodevelopment being assessed by another independent source, such as their 340 
teacher. Furthermore, significant mean effects are mainly seen on individual domains 341 
of the questionnaires, although these sub-domains mostly relate to hyperactivity.   342 
 343 
In the two RCTs (12, 13) of the effects of SGTF treatment on child outcomes, neither 344 
reported any differences (mean scores) in behavior, social competency or attention in 345 
children of treated and untreated mothers at age 3 and 5 respectively. Our results in 346 
children aged 9 confirm both studies and demonstrate that behavior scores at age 3 347 
predict 30% of the variability in behavior scores at age 9.  348 
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 In contrast to other studies, we found no differences in ADHD (3,15-18) and ASD 349 
(20,21) questionnaire domains between the SGTF and normal-GTF groups. However, 350 
we recognise that our findings are based on a smaller sample size, particularly of 351 
normal-GTF, than the large observational cohorts. 352 
A small number of mothers in our study had overt hypothyroidism (n=19) and their 353 
children, whether in the untreated or over-treated groups, had more conduct, total 354 
ADHDq and hyperactivity symptoms then those in the normal-GTF group 355 
(supplemental material). In studies of congenital hypothyroidism, similar findings have 356 
also been reported: increased hyperactivity with higher levothyroxine dosages (49), 357 
and if the child had a high T4, they were significantly more distractible (50). Haddow 358 
et al.(3) identified more children with attention difficulties born to mothers who were 359 
treated in pregnancy, compared to untreated; however this was not an RCT and there 360 
was limited information on thyroid hormone levels of those who were treated. Recent 361 
research confirms that both high and low maternal FT4 may be detrimental to offspring 362 
in respect of intelligence and brain morphology (26). Our results also hint at a biphasic 363 
effect of maternal FT4 on neurodevelopment as illustrated by the switch from negative 364 
to positive association between FT4 and measures of hyperactivity before and after 365 
initiation of treatment. Mothers received a starting Levothyroxine dose of 150 µg daily 366 
after which the dose was adjusted to maintain TSH in the lower end of the reference 367 
range according to recommended treatment targets at the time of the study (54). This 368 
resulted in one third having an FT4 concentration above 17.7pmol/L, a threshold 369 
derived from the top 2.5th percentile of the UK CATS-I cohort (n=16 346), a cohort 370 
larger than those used to set reference ranges, and which excluded mothers with a 371 
history of thyroid disease. Thus subclinical hyperthyroidism may have inadvertently 372 
been induced in the over-treated group (based on current guidelines of a TSH value 373 
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<0.1mIL/I (55). A nationwide study in Europe (n=857, 014) reported that if the mother 374 
was hyperthyroid throughout pregnancy, the child was at an increased risk (OR 1.23, 375 
1.05 to 1.44) of being diagnosed with ADHD (20). Yau et al.(25) reported that lower 376 
maternal TSH values were associated with more ASD symptoms in the offspring; 377 
whilst individuals with resistance to thyroid hormone (n=75) displayed a significant 378 
positive correlation between T4 levels and both ADHD hyperactivity and impulsivity 379 
symptoms (56). The same study also found a significant positive correlation between 380 
T3 and both ADHD hyperactivity and impulsivity in individuals without resistance to 381 
thyroid hormone (case family members, n=77). Thus, our results confirm these earlier 382 
studies indicating that higher levels of thyroid hormones can affect ADHD symptoms. 383 
Our results are relevant to clinicians managing pregnant women with hypothyroidism. 384 
If a woman is already prescribed levothyroxine before pregnancy, current guidelines 385 
(55) advise an increase in the levothyroxine dose of 20-30% during pregnancy. 386 
Recommended starting doses for women diagnosed during pregnancy range from 100   387 
µg for OH but 25-50 µg daily for subclinical hypothyroidism and depend on ‘normal 388 
reference ranges’ for T4 and TSH according to geographic region and ethnic origin 389 
(57,58). In all cases treatment focuses on reducing TSH levels, and FT4 levels are 390 
seldom monitored, hence over-treatment in pregnancy may be more commonplace 391 
than anticipated (57,59,60). Of note, 17% of the women found to be over-treated in 392 
the present study had TSH values within the normal reference range. We hypothesise 393 
that there could be a beneficial mid-range of maternal FT4 during pregnancy for the 394 
offspring; too little or too much may affect the child. To investigate a possible ‘tipping 395 
point’, when differences in mental health and neurodevelopment between groups were 396 
no longer significant, FT4 thresholds of 17, 16, 15 and 14pmol/L at 20 weeks’ gestation 397 
were applied (supplemental data table 5). It was identified that most differences 398 
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diminished below the 17.7pmol/L category, with lowering FT4 also increasing 399 
questionnaire scores; this also supports the biphasic effect of maternal FT4.  400 
While screening and treatment of thyroid dysfunction in pregnancy will clearly benefit 401 
patients with overt hypothyroidism, the benefits for SGTF remain to be proven. In the 402 
light of our findings screening programmes should be carefully considered in order to 403 
avoid the unintended consequences of over-treatment. To fully explore the impact of 404 
SGTF and its treatment on behavioral problems requires large-scale studies with early 405 
intervention. Before embarking on such studies, consensus needs to be reached on 406 
trimester-specific reference ranges for TSH, FT4 and FT3, all derived from large 407 
groups of healthy women, free of thyroid autoantibodies, in an iodine sufficient area 408 
and with no history of thyroid disease.  409 
We conclude that SGTF and optimal management of levothyroxine treatment during 410 
pregnancy have no effect on ADHD and ASD-symptoms of offspring at age 9. The 411 
children of women with FT4>97.5th percentile had more conduct, ADHDq, and ASD-412 
symptoms and suggests that levothyroxine dose in pregnancy needs to be carefully 413 
monitored.  414 
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Figure 1: Flow diagram of the CATS studies showing UK participants only. 622 
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recruitment and following several weeks of thyroxine treatment. 624 
Table 1: Characteristics of the cohort.  625 
Table 2: Group total scores for the questionnaires  626 
Table 3: High questionnaire scores from the normal gestational thyroid function 627 





Characteristics of the follow-on cohort 
The SGTF groups were compared between first participation of offspring, and at follow-up (current). The 
sample appeared mostly similar between the two time points (table 1). Those in the treated SGTF group who 
continued participation into the follow-up of CATS had significantly raised TSH values. A potential reason for 
this could have been that those who felt most benefit from treatment, continued to aid the study. The mothers in 
the untreated SGTF group who participated in the follow-up were significantly older at time of pregnancy 
consent compared to the original CATS sample, this was by an age increase of 1.1 years.   
Table 1 | Comparison of study population to original cohort. Figures are mean values (standard 
deviation). P for difference by t-test unless stated otherwise. 
Characteristics  Treated SGTF P for difference Untreated SGTF P for difference 


























Mother age  29.8 (5.6) 30.2 (5.1) 0.447 29.8 (5.4) 30.9 (4.8) 0.050 (95% CI -
0.002, 2.364) 









Maternal FT4  11.8 (1.8) 12.0 (1.9) 0.262 12.0 (1.9) 11.7 (1.9) 0.310 
*Significance tested by chi square.  
**The social deprivation scores used were calculated from postcodes at time of pregnancy, rather than the 
participants’ current deprivation scores as used in the main analysis. 
†Significance for TSH at consent test by Mann Whitney. 
SGTF=suboptimal gestational thyroid function, CATS=controlled antenatal thyroid screening, TSH=thyroid 
stimulating hormone, FT4= free thyroxine 
 
Thyroid function tests during pregnancy of the treated suboptimal gestational thyroid function group 
Thyroid function tests in pregnancy in the treated SGTF group were analysed by repeated measures ANOVAs 
(FT4) and Friedman’s test (TSH).  
Mean (SD) FT4 levels at time of consent, at 20 weeks’ gestation, and 30 weeks’ gestation were 12.0pmol/L 
(1..91), 16.2pmol/L (2.89), and 15.5pmol/L (2.47), respectively). Maternal FT4 was different at the multivariate 
level throughout pregnancy for the treated SGTF group (Pillai’s Trace=0.687, F(2,116)=127.93, P=0.001, 
ηp2=0.687). Pairwise comparisons that were Bonferroni corrected, identified that at time of consent FT4 was 
significantly lower than at 20 weeks gestation (P=0.001, -5.038 to -3..627), and 30 weeks gestation (P=0.001, -
4.151 to -2.929). FT4 at 20 weeks gestation was significantly higher than at 30 weeks gestation (P=0.003, 0.231 






Fig 1|Mean free thyroxine (T4) values of the treated suboptimal gestational thyroid function group taken at: (1) 
consent into the Controlled Antenatal Thyroid Screening study (median 12 weeks 3 days gestation), (2) 20 
weeks (0 days) gestation, and (3) 30 weeks (1 day) gestation. T4 was measured in pmol/L.  
There was a statistically significant difference in TSH levels throughout the pregnancies of those from the 
treated SGTF group, χ2(2)=173.207, P=0.001. Post hoc analysis with Wilcoxon signed-rank tests was conducted 
with a Bonferroni correction applied, resulting in a significance level at P<0.017. Median (IQR) TSH levels at 
time of consent, 20 weeks gestation, and 30 weeks gestation were 4.1mIU/L (1.9 to 5.1), 0.3mIU/L (0.1 to 1.0), 
and 0.3mIU/L (0.03 to 0.9), respectively. There was a significant difference between TSH at time of consent and 
at 20 weeks gestation (Z=-9.543, P=0.001), as well as at 30 weeks gestation (Z=-9.478, P=0.001). There was 
also a significant difference between TSH at 20 weeks gestation and 30 weeks gestation (Z=-3.109, P=0.002), 




Figure 2 |Median thyroid stimulating hormone (TSH) values of the treated suboptimal gestational thyroid 
function group taken at: (1) consent into the Controlled Antenatal Thyroid Screening study (median 12 weeks 3 
days gestation), (2) 20 weeks (0 days) gestation, and (3) 30 weeks (1 day) gestation. TSH was measured in 
mIU/L.  
Supplementary Statistics 
All analyses in this section deal with continuous data; therefore are MANCOVAs and include Bonferroni 
corrections where applicable. The reported statistical test used in the MANCOVAs was Pillai’s trace, V. Every 
analysis was adjusted for the same covariates as in the main article (child gender, mother age at time of consent, 
whether the mother breastfed for over one month, and social deprivation). Analyses followed the same pattern, 
three CATS groups compared for the three total questionnaire scores, then a secondary MANCOVA exploring 
all questionnaire domains with the treated SGTF split into optimal and over-treatment. Exploration of specific 
maternal FT4 ranges only included the latter MANCOVAs. 
Subclinical hypothyroidism  
Women identified as having subclinical hypothyroidism during their pregnancies, had a TSH >97.5th and FT4 
>2.5th percentiles at time of consent.  In the treated SGTF group, 57.26% (n=67) were in this category, and 
49.00% (n=49) of the untreated SGTF group. There was no difference between the normal GTF, treated, and 
untreated subclinical hypothyroid groups for total questionnaire scores (P=0.909). When exploring the effect of 
treatment to the 17.7pmol/L threshold, there was also no difference in mean scores (P=0.128). See table 2 for 
descriptive data.   
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Table 2 | Mean scores for the subclinical hypothyroid and normal GTF groups. Figures are mean 
values (standard deviation).  
Questionnaire domain  Subclinical hypothyroidism  













     
   Emotion 2.32 (2.24)  2.32 (2.18) 2.22 (1.98) 2.50 (1.73) 
   Conduct 1.21 (1.50)  1.33 (1.39) 1.44 (1.83) 1.92 (1.83) 
   Hyperactivity 3.09 (2.52)  3.47 (2.61) 3.10 (2.91) 4.23 (2.55) 
   Peer problems 1.58 (1.88)  1.10 (1.29) 1.51 (1.90) 1.00 (1.02) 
   Total difficulties 8.20 (6.01) 8.81 (5.71) 8.22 (5.41) 8.27 (6.13) 9.65 (4.97) 
   Prosocial                          8.78 (1.78)  8.47 (2.09) 8.90 (1.71) 8.69 (1.93) 
Child ADHD 
questionnaire 
     
   Inattention 6.07 (5.67)  5.75 (4.94) 5.88 (5.84) 7.62 (5.73) 
   Overactivity 2.05 (2.29)  2.37 (2.42) 2.41 (2.88) 3.58 (3.14) 
   Impulsivity 3.13 (2.79)  3.34 (2.50) 3.68 (3.55) 4.38 (3.28) 
   Total 11.25 (9.53) 13.37 (11.20) 11.46 (8.52) 11.98 (11.45) 15.58 (10.63) 
Social communication 
questionnaire 
4.28 (3.70) 4.59 (4.14) 3.95 (2.96) 4.05 (3.73) 5.43 (4.65) 
SGTF=suboptimal gestational thyroid function, ADHD=attention deficit hyperactivity disorder 
 
Maternal hypothyroxinemia 
Women were classified as the having hypothyroxinemia during their pregnancies if their FT4 at consent was 
<2.5th and their TSH was <97.5th percentiles. There were 30.77% (n=36) of the treated SGTF, and 44.00% 
(n=44) of the untreated SGTF group in this category. Total questionnaire scores were not significantly different 
between the normal GTF, treated and untreated hypothyroxinaemia groups P=0.207, see table 3 for scores). 
There was also no difference when treatment was explored between the groups (P=0.105).   
Table 3 | Mean questionnaire scores for the hypothyroxinemic and normal GTF groups. Figures are 
mean values (standard deviation). 
Questionnaire domain  Hypothyroxinemic   













     
   Emotion 2.32 (2.24)  2.11 (1.94) 2.41 (2.10) 2.90 (2.33) 
   Conduct 1.21 (1.50)  1.05 (1.40) 1.50 (1.73) 1.70 (1.83) 
   Hyperactivity 3.09 (2.52)  3.30 (2.79) 3.69 (2.81) 4.30 (4.06) 
   Peer problems 1.58 (1.88)  1.20 (1.32) 1.31 (1.87) 1.00 (1.33) 
   Total difficulties 8.20 (6.01) 9.18 (7.17) 7.66 (5.40) 8.91 (6.83) 9.90 (8.35) 
   Prosocial                          8.78 (1.78)  9.02 (1.25) 8.73 (1.93) 9.40 (1.07) 
Child ADHD 
questionnaire 
     
   Inattention 6.07 (5.67)  4.79 (4.63) 6.75 (6.32) 6.90 (7.84) 
   Overactivity 2.05 (2.29)  2.38 (2.82) 2.31 (2.62) 3.40 (4.14) 
   Impulsivity 3.13 (2.79)  2.93 (3.04) 3.42 (2.87) 4.10 (4.04) 
   Total 11.25 (9.53) 13.02 (12.29) 10.10 (9.25) 12.48 (10.99) 14.40 (15.78) 
Social communication 
questionnaire 
4.28 (3.70) 5.98 (5.21) 4.26 (2.89) 6.47 (5.44) 4.70 (4.55) 
SGTF=suboptimal gestational thyroid function, ADHD=attention deficit hyperactivity disorder 
 
Overt hypothyroid groups 
As the CATS study classified women with FT4 <2.5th and/or TSH >97.5th percentiles for a positive result of 
SGTF, the secondary analysis examined questionnaire scores by women who had overt hypothyroidism (OH, 
FT4 <2.5th and TSH >97.5th). OH, though uncommon during pregnancy (3 in 1000(1)), is the most severe 
underactive thyroid function. There were 8.55% (n=10) of the treated SGTF group, and 9.00% (n=9) of the 
untreated SGTF group classified as having OH. Comparing these groups with the normal GTF for total 
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questionnaire scores identified a significant difference at the multivariate level (V=0.063, F(6,496)=2.669, 
P=0.015, ηp2=0.031), with a difference found for ADHD Total scores (F(2,249)=4.680, P=0.010, ηp2=0.036). 
The untreated OH group had significantly higher scores compared to the normal GTF for ADHD Total (P=0.022 
(0.945, 16.876)). 
When exploring the effect of treatment to the 17.7pmol/L threshold for maternal FT4, there was a sustained 
difference at the multivariate level (V=0.203, F(27,726)=1.948, P=0.003 ηp2=0.068). At the univariate level 
SDQ Conduct (F(3,248)=4.402, P=0.005, ηp2=0.051), ADHD Hyperactivity (F(3,248)=5.665, P=0.001, 
ηp2=0.064), and ADHD Total (F(3,248)=3.487, P=0.016, ηp2=0.040) were significantly different. The over-
treated OH group had significantly higher scores for SDQ Conduct (P=0.038 (0.072, 4.273) and ADHD 
Hyperactivity (P=0.020 (0.357, 6.597) compared to the normal GTF. Again, for ADHD Total, the untreated OH 
had significantly higher scores than the normal GTF (P=0.045 (0.117, 7.693).  
Children born to mothers who were untreated for OH in pregnancy, had higher scores for the Child ADHD 
Questionnaire, optimal treatment improved this with some means moving closer to those of the normal GTF 
(table 4). Over-treatment for OH had a significant effect here on domains found with the entire SGTF sample; 
SDQ Conduct and ADHD Hyperactivity. Caution is advised as the sample sizes are small for OH. 
 
 
Exploratory analysis; treatment by target range 
The following analyses explored potential limits of treatment for minimising specific neurodevelopmental 
symptoms in the child.  Analyses were again MANCOVAs with the same four covariate adjustments.  
Table 4 | Questionnaire scores for the normal gestational thyroid function (GTF) group, and treated and 
untreated overt hypothyroid group. Figures are mean values (standard deviation).  




Optimally treated Over-treated 
 N=237 N=10 N=9 N=6 N=4 




     
   Emotion 2.32 (2.24)  2.78 (1.64) 2.67 (2.94) 3.25 (3.30) 
   Conduct 1.21 (1.50)  2.44 (2.07) 0.83 (0.98) 3.25* (2.99) 
   Hyperactivity 3.09 (2.52)  5.11 (3.37) 4.33 (2.16) 4.25 (4.35) 
   Peer problems 1.58 (1.88)  1.33 (1.22) 1.33 (1.97) 0.50 (1.00) 
   Total difficulties 8.20 (6.01) 10.00 (8.51) 11.67 (7.16) 9.17 (7.08) 11.25 (11.41) 
   Prosocial                          8.78 (1.78)  8.44 (1.33) 9.17 (1.33) 8.50 (3.00) 
   Inattention 6.07 (5.67)  11.44 (6.77) 7.32 (5.44) 9.25 (9.98) 
   Hyperactivity 2.05 (2.29)  4.11 (3.48) 4.00 (2.61) 5.25* (4.19) 
   Impulsivity 3.13 (2.79)  5.22 (3.31) 2.17 (1.83) 5.25 (4.50) 
   Total 11.25 (9.53) 15.99 (12.67) 20.78* (12.10) 13.48 (8.29) 19.75 (18.32) 
Social communication 
questionnaire 
4.28 (3.70) 6.70 (8.08) 4.00 (2.78) 6.17 (5.85) 5.72 (8.21) 
*Significantly higher (P<0.05) group results (from columns left to right) 
SGTF=suboptimal gestational thyroid function, ADHD=attention deficit hyperactivity disorder 
Untreated overt hypothyroid (1) Child ADHD questionnaire (ADHD) Inattention, higher than Normal GTF, (2) 
ADHD Total, higher than Normal GTF, (3) Strengths and difficulties questionnaire Conduct, higher than 
Normal GTF. 
Treated overt hypothyroid ADHD Hyperactivity and SDQ Conduct, higher than Normal GTF. Untreated overt 
hypothyroid ADHD Total, higher than Normal GTF. 
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As can be seen in table 5, the means of the treated group decreased with decreasing FT4 threshold values. This 
confirms the main conclusions from the article that over-treatment could have an impact for the child’s 
neurodevelopment; as well as the threshold of 17.7pmol/L in pregnancy being the most ‘detrimental’. As 
thresholds decreased, interestingly, those who were treated up to the thresholds increased questionnaire scores. 
This supports a theory of ‘U-curved effects’(2); demonstrating that higher and lower values of maternal FT4 can 
affect the child. A further possible mechanism could be that those born to mothers with the lowest FT4 had 
more of an effect to the group mean with decreasing groups with lowering FT4 thresholds. SDQ Peer problems 
being significantly higher in the normal GTF group were repeatedly found compared to above thresholds for 
maternal FT4. At the whole group level of the treated SGTF, TSH was positively correlated to SDQ Peer 
problems at 30 weeks’ gestation. As the FT4 levels were high, TSH would have been lowering, and supporting 
the correlation, the lower the TSH level, the lower SDQ Peer problem scores will have been. 
Over 17pmol/L in pregnancy 
For the first threshold of 17pmol/L (n=53), there was a significant difference between the questionnaire scores 
at the multivariate level (V=0.114, F(27,1320)=1.922, P=0.003, ηp2=0.038). Univariate analyses identified 
difference for SDQ Peer problems (F(3,446)=3.942, P=0.009, ηp2=0.026) and ADHD Overactivity 
(F(3,446)=4.229, P=0.006, ηp2=0.028). Bonferroni corrected pairwise comparisons evidenced that the normal 
GTF had a higher group mean than those born to mothers with FT4 values >17pmol/L (P=0.040, 0.019 to 
1..363), but the effect was inversed for ADHD Overactivity (P=0.003, 0.324 to 2.340).  
Over 16pmol/L in pregnancy 
The lower threshold 16pmol/L (n=70) also yielded a difference at the multivariate level for questionnaire scores 
(V=0.127, F(27,1320)=2.162, P=0.001, ηp2=0.042). The domains with significant differences were, SDQ Peer 
problems (F(3,446)=4.755, P=0.003, ηp2=0.031) and ADHD Overactivity (F(3,446)=3.851, P=0.010, 
ηp2=0.025). Significance persisted following Bonferroni corrections, and akin to FT4 values >17pmol/L 
throughout pregnancy, SDQ Peer problems were higher in the normal GTF compared to those mothers with FT4 
values >16pmol/L SGTF (P=0.015, 0.088 to 1.289), with those >16pmol/L having higher scores compared to 
the normal GTF group for ADHD Overactivity (P=0.006, 0.226 to 2.034). 
Over 15pmol/L in pregnancy 
The lowered threshold of 15pmol/L (n=87) was used for the following analysis. The MANCOVA identified a 
difference between the groups (V=0.115, F(27,1320)=1.941, P=0.003, ηp2=0.038). Univariate and pairwise 
comparison analyses identified differences for SDQ Peer problems (F(3,446)=5.871, P=0.001, ηp2=0.038, 
normal GTF higher than those with maternal FT4 values >15pmol/L SGTF, P=0.009, 0.113 to 1.220), and SCQ 
(F(3,446)=2.872, P=0.036, ηp2=0.019, children born to mothers with FT4 <14.9pmol/L scored higher than the 




Table 5| Mean questionnaire scores for thresholds of FT4 in pregnancy. Figures are mean values (standard deviation). 
Questionnaire domain     Treatment thresholds  













Strengths and difficulties 
questionnaire 
        
   Emotion 2.32 (2.24) 2.24 (2.01) 2.58 (1.96) 2.28 (2.13) 2.46 (2.08) 2.35 (2.02) 2.34 (2.02) 2.62 (2.16) 
   Conduct 1.21 (1.50) 1.27 (1.42) 1.60 (1.84) 1.59 (1.81) 1.43 (1.73) 1.84 (1.93) 1.44 (1.70) 2.03 (2.09) 
   Hyperactivity 3.09 (2.52) 3.51 (2.74) 3.91 (3.03) 3.48 (2.80) 3.73 (3.06) 3.60 (2.67) 3.61 (3.00) 3.87 (2.62) 
   Peer problems 1.58 (1.88) 1.16 (1.28) 0.92 (1.03) 1.48 (1.96) 0.91 (1.21) 1.70 (2.02) 0.93 (1.33) 2.10 (2.07) 
   Total difficulties 8.20 (6.01) 8.18 (5.42) 9.02 (6.15) 8.83 (6.65) 8.53 (6.28) 9.49 (6.61) 8.33 (6.25) 10.62 (6.64) 
   Prosocial                          8.78 (1.78) 8.73 (1.72) 8.89 (1.70) 8.72 (1.81) 9.09 (1.55) 8.47 (2.00) 9.05 (1.52) 8.23 (2.25) 
Child ADHD questionnaire         
   Inattention 6.07 (5.67) 5.83 (5.25) 7.21 (6.51) 6.24 (5.76) 6.79 (6.44) 6.52 (5.62) 6.34 (6.19) 7.65 (5.83) 
  Overactivity 2.05 (2.29) 2.53 (2.73) 3.34 (3.45) 2.41 (2.62) 3.17 (3.41) 2.32 (2.35) 2.79 (3.25) 2.93 (2.42) 
   Impulsivity 3.13 (2.79) 3.32 (2.85) 3.92 (3.67) 3.55 (2.98) 3.91 (3.56) 3.43 (2.89) 3.69 (3.39) 3.80 (3.08) 
   Total 11.25 (9.53) 11.67 (9.50) 14.47 (12.78) 12.20 (10.30) 13.87 (12.66) 12.27 (9.56) 12.83 (12.03) 14.38 (9.89) 
Social communication 
questionnaire 
4.28 (3.70) 4.09 (2.89) 4.84 (5.06) 5.41 (4.81) 4.72 (4.75) 5.80 (5.13) 4.66 (4.82) 6.57 (4.99) 
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Table 1 | Characteristics of the cohort. Values are means 





















 N=246 N=125 N=104    
TSH at study 








0.001 0.001 0.003 

















Age of mother 































65.3 58.9 56.3 0.226 0.113 0.697 
Male children 
(%) 











0.003 0.017 0.996 
†Median and interquartile ranges presented. 
*missing per group, n=1 
Confidence intervals presented for continuous data only. Current free thyroxine 
reference ranges for adults during pregnancy per trimester are as follows: first 
trimester 10.5-18.3pmol/L, second trimester 9.5-15.9pmol/L, third trimester 8.6-
13.7pmol/L (serum TSH and FT4 were measured with the use of 
Immunochemiluminescence, ADVIA Centaur, Siemens Healthcare Diagnostics). 
SGTF= suboptimal gestational thyroid function, TSH=thyroid stimulating hormone, 
FT4=free thyroxine 
 
 Table 2 | Group total scores for the questionnaires. 


































4.09 (2.89) 0.08 
*Total difficulties score  
Table 3 | High questionnaire scores from the normal gestational thyroid function (GTF), treated, and 
untreated suboptimal GTF groups. Figures are numbers (percentages).  
Questionnaire 
domain 









     
   Emotion      
 High*/very high 39 (16.4) 19 (16.3) 13 (13.0) 11 (14.3) 8 (20.0) 
   Conduct      
   High/very high 20 (8.5) 18 (15.4)^ 7 (7.0) 9 (11.7) 9 (22.5)^^^ 
   Hyperactivity      
   High/very high 15 (6.3) 16 (13.7)^ 10 (10.0) 10 (13.0) 5 (12.5) 
   Peer problems      
   High/very high 39 (16.4) 13 (11.1) 7 (7.0) 12 (15.6) 1 (2.5) 
   Total 
difficulties 
     
   High/very high 28 (11.8) 16 (13.7) 8 (8.0) 10 (13.0) 6 (15.0) 
   Prosocial                              
      Low/very low 27 (11.4) 13 (11.1) 10 (10.0) 8 (10.4) 5 (12.5) 
Child ADHD 
questionnaire 
     
   Inattention      
      >2SD† 11 (4.8) 9 (7.8) 3 (3.0) 5 (6.5) 4 (10.0) 
   Hyperactivity      
     > 2SD 9 (3.9) 12 (10.2)^ 5 (5.0) 5 (6.5) 7 (17.5)^^ 
   Impulsivity      




     
   Total >15 4 (1.7) 7 (6.0)^ 1 (1.0) 4 (5.2) 3 (7.5)^^ 
SGTF=suboptimal gestational thyroid function normal-GTF = normal gestational thyroid function 
*high = 90-95th percentile, as calculated by the SDQ (scores >90th percentile are clinically significant); very 
high>95th percentile, as calculated by the SDQ 
†SDs calculated by Thapar and colleagues 
^p<0.05 treated versus normal-GTF  
^^p<0.05 over-treated versus untreated SGTF  
^^^ p< 0.01 over-treated versus untreated SGTF 
 
 
